Senior/Executive Director – Immune-Oncology and Oncology

Cambridge, MA
Jun 08, 2021
Science/R&D, Oncology
Required Education
Position Type
Full time
Cygnal, a new biology platform company, was founded by Flagship Pioneering to pioneer the field of exoneural biology – the impact of the peripheral nervous system on cancer, the immune system, metabolism, and regeneration. The company is applying cutting-edge neuroscience to elucidate novel therapies to treat cancer progression and metastasis, autoimmune conditions, inflammation, and other diseases.

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.4 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions. The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).

The Position

Cygnal Therapeutics is seeking a highly motivated and experienced biologist to lead our team to identify new targets for therapeutic intervention and discover novel therapies for oncology and immune-oncology. The successful candidate will report to the Senior Vice President of Drug Development and be a self-starter who thrives in a highly collaborative and fast paced environment.

Key Responsibilities

  • Provide scientific leadership on the execution of target identification and validation efforts in the areas of oncology and immune-oncology, in the context of Exoneural Biology
  • Oversee the development of in vitro assays required for the identification and validation of novel therapeutic targets
  • Provide support to therapeutic development programs in the areas of oncology and immune-oncology
  • Lead and mentor a team of direct reports and work closely and collaboratively in a multi-disciplinary team of biologists, Biologics scientists, medicinal chemists, bioinformaticians and pharmacologists
  • Work with cross-functional teams to ensure timely execution and communication of research results with high quality standards
  • Interface with pharma partners, clinical and academic collaborators, and CROs

Minimum Qualifications

  • PhD degree in immunology, biology, or related field
  • 10+ years of relevant industry experience in large pharma and/or biotech
  • Strong understanding of oncology and immuno-oncology biology and substantial knowledge of relevant assays, model systems and resources
  • Extensive experience in discovery/preclinical-stage development of immune-modulating antibodies and/or small molecules for cancer
  • Proven ability to manage timelines and resources to drive projects toward key decision point
  • Ample experience in writing Study Reports and making scientific presentations; strong verbal and written communication skills with ability to clearly articulate scientific viewpoints to diverse audiences

Preferred Qualifications

  • Drug discovery experience in the field of oncology or immune-oncology
  • Demonstrated contributions to therapeutic monoclonal antibody development
  • Excellent scientific track record of high impact, peer-reviewed publications and patents
RECRUITING & STAFFING AGENCIES: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.